NCT04841902Completed
Effects of Life Style Intervention Manual in Pre Hypertensive Sedentary Population
Effects of Life Style Intervention Manual on Metabolic, Cardiovascular, Respiratory and Physical Parameters in Pre Hypertensive Sedentary Population
Source: ClinicalTrials.gov · Last updated 19 Apr 2024
Brief summary (registry, in English)
Hypertension is an increasingly important medical and public health issue. The prevalence of hypertension increases with advancing age to the point where more than half of people 60-69 years of age and approximately three-fourths of those 70 years of age and older are affected. The age related rise in SBP is primarily responsible for an increase in both incidence and prevalence of hypertension with increasing age. At present, it is estimated that about 1 billion people worldwide have hypertension (\>140/90 mmHg), and this number is expected to increase to 1.56 billion by 2025. Because of the new data on lifetime risk of hypertension and the impressive increase in the risk of cardiovascular complications associated with levels of BP previously considered to be normal, the JNC 7 report has introduced a new classification that includes the term "prehypertension" for those with BPs ranging from 120-139 mmHg systolic and/or 80-89 mmHg diastolic. This new designation is intended to identify those individuals in whom early intervention by adoption of healthy lifestyles could reduce BP, decrease the rate of progression of BP to hypertensive levels with age, or prevent hypertension entirely. Prehypertension is not a disease category. Rather, it is a designation chosen to identify individuals at high risk of developing hypertension, so that both patients and clinicians are alerted to this risk and encouraged to intervene and prevent or delay the disease from developing. Individuals who are pre hypertensive are not candidates for drug therapy based on their level of BP and should be firmly and unambiguously advised to practice lifestyle modification in order to reduce their risk of developing hypertension in the future. The goal for individuals with prehypertension and no compelling indications is to lower BP to normal levels with lifestyle changes, and prevent the progressive rise in BP using the recommended lifestyle modifications.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 240 (actual)
- First submitted
- 29 Mar 2021
- Start date
- 1 Jul 2021
- Primary completion date
- 30 Nov 2023
- Lead sponsor
- Riphah International University
- Diseases
- High blood pressure
- NCT number
- NCT04841902
What you commit to
- Study type: Interventional
- Participants enrolled: 240
- From 1 Jul 2021 to the primary completion date, 30 Nov 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Evidence of target organ damage such as left ventricular hypertrophy, angina, heart failure, stroke, chronic kidney disease, peripheral artery disease
Age
- Women of child-bearing age who tested positive for HCG \& breastfeeding women
Other
- Body Mass Index less than 18.5 kg/m2 or greater than 45 kg/m2
- Individuals who could not read the consent or Participated in another study within 3 months
Who the study is looking for
- Aged between 25 - 40 years
- Either gender
- Clinic BP will be consistent with the diagnosis of pre-hypertension
- Sedentary Subjects (\<150 min/week or \<600 MET-min/week on IPAQ Urdu Version)
Age in the registry: 25 years to 40 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Riphah Rehabiliation Clinic Coordinator of this site? Confirm its status | Lahore | Pakistan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.